Karyopharm Therapeutics Inc.
KPTIQ· OTC
Released Aug 2, 2023, before the open
10-Q filed Aug 2, 2023, 33 days after period end · 0000950170-23-036780
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $37.58M | $39.68M | $22.60M | $33.51M |
| Net Income | -$32.63M | -$49.06M | -$53.58M | -$46.43M |
| EPS Diluted |
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR
| -$0.29 |
| -$0.62 |
| -$0.71 |
| -$0.63 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.